MP Advisors is an independent company offering research and paramount knowledge within a healthcare industry. At present great many global pharmaceutical companies, especially in U.S., Europe, Russia, India and Japan are among MP Advisors’s clients. When founded, 1996, the agency is ensuring investment solutions and assessing investment opportunities with a penetrating eye on risks and benefits from funding pharma manufacturing.
MP Advisors unparalleled service includes:
- Financial Analysis;
- Competitive landscaping;
- Macro Analysis;
- Technology Transfer;
- Mergers & Acquisitions;
- Strategic planning;
- Forecast.
Customized reports are in the focus area of skillful and competent experts who explore, analyze and interpret data, select tools and approaches on how efficiently reach ultimate market decisions and reach maximum understanding of current biotech and therapeutic issues.
More than 200 medical companies’ profiles are in its database. MP Advisors publishes insightful reports fortified by proficient views of key specialists. Moreover, it produces ad hoc reports on Japan and Indian generic drug, Para IV, oncology, obesity and other therapy reviews.
Publications found:
456
Sort by:
RANBAXY'S PARA IV PIPELINE ANALYSIS
US$ 350.00
Ranbaxy has a pipeline of ~19 Para IV challenges, of which 12 are FTF’s. The total branded sales of these drugs under Para IV challenge by Ranbaxy is approximately $25b. Most of these Para ... offer decent upside. We expect Ranbaxy to generate a cumulative PAT of ~$950m from these Para IV opportunities, which is ...
June 2011
22 pages
Sun Pharma's Para IV Pipeline Analysis
US$ 350.00
Sun Pharma has the pipeline of ~29 Para IVs having branded sales of ~$25b. Among its Para IV pipeline the confirmed opportunities (branded sales of ~ $7.8b) are Gleevec, Namenda, Comtan, ...
June 2011
27 pages
Tarcva - EURTAC Data positive: Threat to Iressa in Firstline NSCLC
US$ 140.00
... by 63 % compared to chemotherapy (9.7 m vs 5.2 m). Interim analysis of EURTAC trial showed that Tarceva improved the overall survival by 4 m (22.9 m ... vs 18.8 m) compared to cisplatin chemotherapy. The data poses threat to AZN’s Iressa as it has not demonstrated OS ... lines of EGFR positive advanced NSCLC.
June 2011
2 pages
DISHMAN - Back To Basics
US$ 90.00
We reiterate our Underperform rating on Dishman despite it’s higher than expected Q4 FY11 result. The result was ...
May 2011
5 pages
Lupin Looses Combivir – A Big Blow To An Already Weak FY12 Pipeline
US$ 140.00
... for generic Combivir (Lamivudine + Zidovudine). With this approval, Teva has been granted and Lupin has ... ), Teva will launch its generic in Q4CY11. Lupin will be able to enter only after the 180 ... all other generics as well. We reiterate our Underperform on Lupin with target price of Rs.360 on the back of (1) ...
May 2011
2 pages
Global Pharmaceutical & Biotechnology Outlook 2011
US$ 10,000.00
... strategic and long term investment decision making of senior management. Outlook-11’ has been tailored to deliver more meaningfully in the ... for the future, and their key milestones. The Global Pharmaceutical Model is changing. Major pharmaceutical companies continue to under-perform in a market constrained ...
December 2010
454 pages
